Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$76.94
Market cap
$238.51B
P/E Ratio
36.99
Dividend/share
$1.49
EPS
$2.08
Enterprise value
$265.13B
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
Highlights
The company's gross profit rose by 16% YoY and by 3.3% QoQ
Astrazeneca's revenue has increased by 10% YoY and by 3.2% QoQ
AZN's price to earnings (P/E) is 73% lower than its 5-year quarterly average of 137.9 but 5% higher than its last 4 quarters average of 35.4
AZN's debt is up by 12% year-on-year but it is down by 2.9% since the previous quarter
The quick ratio has declined by 4.3% since the previous quarter
Key stats
What are the main financial stats of AZN
Market
Valuations
Earnings
Shares outstanding
3.1B
Market cap
$238.51B
Enterprise value
$265.13B
Price to earnings (P/E)
36.99
Price to book (P/B)
6.03
Price to sales (P/S)
4.85
EV/EBIT
28.12
EV/EBITDA
18.2
EV/Sales
5.4
Revenue
$49.13B
EBIT
$9.43B
EBITDA
$14.57B
Free cash flow
$9.48B
Per share
Balance sheet
Liquidity
EPS
$2.08
Free cash flow per share
$3.06
Book value per share
$12.75
Revenue per share
$15.85
TBVPS
$14.15
Total assets
$104.34B
Total liabilities
$64.74B
Debt
$33.53B
Equity
$39.51B
Working capital
-$3.17B
Debt to equity
0.85
Current ratio
0.89
Quick ratio
0.66
Net debt/EBITDA
1.83
Margins
Efficiency
Dividend
EBITDA margin
29.7%
Gross margin
82.1%
Net margin
13.1%
Operating margin
18.4%
Return on assets
6.4%
Return on equity
16.8%
Return on invested capital
24.8%
Return on capital employed
12.4%
Return on sales
19.2%
Dividend yield
1.93%
DPS
$1.49
Payout ratio
71.4%
AZN stock price
How has the Astrazeneca stock price performed over time
Intraday
-0.49%
1 week
-1.75%
1 month
-0.26%
1 year
22.03%
YTD
14.24%
QTD
-1.25%
Financial performance
How have Astrazeneca's revenue and profit performed over time
Revenue
$49.13B
Gross profit
$40.33B
Operating income
$9.05B
Net income
$6.44B
Gross margin
82.1%
Net margin
13.1%
AZN's operating income is up by 23% year-on-year and by 3.3% since the previous quarter
The company's gross profit rose by 16% YoY and by 3.3% QoQ
The operating margin has grown by 12% YoY
Astrazeneca's revenue has increased by 10% YoY and by 3.2% QoQ
Growth
What is Astrazeneca's growth rate over time
Valuation
What is Astrazeneca stock price valuation
P/E
36.99
P/B
6.03
P/S
4.85
EV/EBIT
28.12
EV/EBITDA
18.2
EV/Sales
5.4
AZN's price to earnings (P/E) is 73% lower than its 5-year quarterly average of 137.9 but 5% higher than its last 4 quarters average of 35.4
Astrazeneca's EPS has increased by 4.5% YoY
The stock's price to book (P/B) is 16% less than its 5-year quarterly average of 7.2 but 6% more than its last 4 quarters average of 5.7
AZN's equity is up by 6% year-on-year and by 6% since the previous quarter
Astrazeneca's revenue has increased by 10% YoY and by 3.2% QoQ
The stock's price to sales (P/S) is 6% more than its last 4 quarters average of 4.6
Efficiency
How efficient is Astrazeneca business performance
Astrazeneca's return on invested capital has increased by 18% YoY
Astrazeneca's return on sales has increased by 14% YoY
Dividends
What is AZN's dividend history
DPS
$1.49
Dividend yield
1.93%
Payout ratio
71.4%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Astrazeneca financials performed over time
The company's total assets is 61% higher than its total liabilities
The total liabilities has grown by 9% YoY
The company's total assets rose by 8% YoY and by 2% QoQ
AZN's debt is 15% smaller than its equity
AZN's debt is up by 12% year-on-year but it is down by 2.9% since the previous quarter
AZN's debt to equity is down by 8% since the previous quarter but it is up by 6% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.